Evidence map›Paper›PMID 39589860›Full record

ArticleImmunotherapy2024

Identifying risk factors and biomarkers for severe CIP in lung cancer patients- a retrospective case series study.

Guixian Wu, Jingjing Qu, Jing Zheng, Binggen Wu, Ting Wang, Yuncui Gan, Nan Jiang, Yuekang Li, Jinpeng Liu, Jianying Zhou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guixian WuDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Jingjing QuDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Jing ZhengDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Binggen WuDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Ting WangDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Yuncui GanDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Nan JiangDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Yuekang LiDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Jinpeng LiuRadiology Department, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jianying ZhouDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Jianya ZhouDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but they can induce immune-related adverse events, including immune checkpoint inhibitor-associated pneumonia (CIP), a severe lung complication. CIP, particularly Grades 3-4, is associated with poor prognosis, indicating a critical need for research on this issue. Our study aimed to investigate the risk factors and biomarkers associated with severe CIP in lung cancer patients treated with ICIs, where OS represents overall survival and PFS denotes progression-free survival.

methodsWe conducted a retrospective analysis of 106 lung cancer patients with CIP at the First Affiliated Hospital of Zhejiang University from 2019 to 2023, categorized into four severity grades.

resultsThe median time to onset of CIP was 5.17 months. Patients with Grade 3-4 CIP had a median PFS of 6.5 months and OS of 11.2 months. Univariate analysis identified phosphocreatine kinase below 61.5 U/l, Forced Vital Capacity (FVC) below 1.96, and BMI below 21.26 as predictive factors for Grades 3-4 CIP. Multivariate analysis confirmed that a decreased FVC was a significant predictor.

conclusionsA decreased FVC below 1.96 emerged as a predictive factor for Grades 3-4 CIP, highlighting the importance of monitoring FVC in patients receiving ICIs.

Indexed as

Immune Checkpoint InhibitorsLung NeoplasmsAdultAgedAged, 80 and overBiomarkersBiomarkers, TumorFemaleHumansMaleMiddle AgedPneumoniaPrognosisRetrospective StudiesRisk FactorsBiomarkersBiomarkers, TumorImmune Checkpoint Inhibitorsclinical classificationImmune checkpoint inhibitorimmune checkpoint inhibitor-related pneumonitislung cancerrisk factor

Identifiers

PMID39589860
PMCPMC11633429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.